Products
Latest News
FAQ
Log in
|
Search
Search
Filters
Clear All
Study Phase
Early Phase 1
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
Phase 4
Not Applicable
Recruitment Status
Recruiting
Not yet recruiting
Active, not recruiting
Completed
Suspended
Terminated
Withdrawn
Study Type
Interventional
Observational
Expanded Access
Others
Eligibility Sex
All
Female
Male
Healthy Volunteers
All
Include
Exclude
Found
1
clinical trials
|
View Analysis
Sort by:
Newest First
FcRn Antagonists (Efgartigimod) for Acute NMOSD Attack
Phase 2
Not yet recruiting
Conditions
NMO Spectrum Disorder
Neuromyelitis Optica Spectrum Disorder
Neuromyelitis Optica
Interventions
Drug: Efgartigimod Alfa Injection
Drug: High-dose intravenous methylprednisolone
Subscribe
First Posted Date
2024-07-11
Last Posted Date
2024-07-11
Lead Sponsor
Tianjin Medical University General Hospital
Target Recruit Count
63
Registration Number
NCT06497374
Subscribe
Prev
1
Next
© Copyright 2025. All Rights Reserved by MedPath
Home
Terms & Conditions
Privacy Policy